Janssen’s Newly Approved Ponvory Joins Crowded MS Space
Executive Summary
Ponesimod is the fourth S1P modulator approved to treat multiple sclerosis and joins a sprawling class of oral and injectable therapies. But Janssen sees numerous ways to differentiate its drug.
You may also be interested in...
J&J Brings In Multiple Sclerosis Candidate Via Licensing Pact With Pipeline
Deal Snapshot: Pipeline gets $50m up front and a $25m equity investment in exchange for global rights to an M1 receptor antagonist cleared to move into Phase II in relapsing/remitting MS.
MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space
The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.
Pivotal Moment In EU For Potential New Drugs
Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.